US8177631053 - Common Stock
SESEN BIO INC
NASDAQ:SESN (3/7/2023, 6:50:19 PM)
After market: 0.5832 -0.05 (-7.25%)0.6288
+0.04 (+7.29%)
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
SESEN BIO INC
245 1st St Ste 1800
Cambridge MASSACHUSETTS 02142
P: 16174448550.0
CEO: Thomas R. Cannell
Employees: 35
Website: https://sesenbio.com/
Sesen Bio (SESN) stockholders on Thursday approved effecting a 1-for-20 reverse stock split of the company's issued and outstanding shares. Read more here.
Sesen Bio (SESN) announced Thursday that its shareholders greenlighted the company’s pending merger with Carisma Therapeutics at a special stockholder meeting. Read the full story here.
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Here you can normally see the latest stock twits on SESN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: